Can Metabolic Regulators Fight Metastatic Melanoma?

Vemurafenib, an inhibitor of mitogen-activated protein kinase signaling downstream of BRAF V600E , can be successfully used to treat patients with metastatic melanoma. However, it produces a high incidence of therapeutic resistance. New strategies are needed to treat vemurafenib-resistant melanoma, so researchers used two bioactive compound libraries and identified two possible targets: deguelin and rotenone. "Breakthroughs in understanding the molecular basis for the disease have led to a coupl...
Continue reading

Synthesizing a Marine Sponge Compound that Fights Cancer

Halichondrins, natural products isolated from marine sponges, have demonstrated antitumor activity both in live mice and in human cancer cell cultures. Previously, the limited supply of halichondrins has made it difficult to develop drugs utilizing their antitumor activity. However, after 30 years of research, scientists have now been able to harvest the tumor-fighting capabilities of halichondrins by incorporating a synthesized version into a drug called E7130. When halichondrins were first dis...
Continue reading

Can Artificial Intelligence Diagnose Skin Lesions? With Philipp Tschandl, MD, PhD

​ Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artificial neural networks— outperform humans, even experts, in the classification of pigmented skin lesions . In this interview with i3 Health, Philipp Tschandl, member of the Vienna Dermatologic Imaging Research (ViDIR) Group of the Medical University of Vienna's Department of Dermatology, discusses the significance of the s...
Continue reading

AI Beats Human Experts in Classifying Skin Lesions

A new study reports that artificial intelligence (AI) in the form of machine-learning algorithms outperforms human experts in the diagnosis of pigmented skin lesions. This web-based study, which was published in The Lancet Oncology , included 511 human readers from 63 countries. Of these, 55.4% were board-certified dermatologists, 23.1% were dermatology residents, and 16.2% were general practitioners. The human readers were asked to diagnose dermatoscopic images that had been randomly selected i...
Continue reading

Metastatic Melanoma: Dabrafenib/Trametinib Improves Outcomes

Historically, patients with metastatic melanoma have a poor prognosis. However, due to the development of BRAF- and MEK-targeted therapies, patient outcomes have improved. To further characterize the outcomes associated with these treatments, researchers compiled and analyzed data from two clinical trials and found that in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, dabrafenib plus trametinib had many long-term benefits in about one third of patients. D...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.